로딩 중…
지수 로딩 중…
BIFIDO Co., Ltd.
238200· KOSDAQ· Consumer Staples· Household & Personal Products
₩2,530+0.80%
2026-06-19
Price Chart
BIFIDO Co., Ltd.-24.02%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 20.70B KRW |
| Revenue | 17.23B KRW |
| Net Income | -914.0M KRW |
| Total Assets | 57.01B KRW |
| Net Assets | 44.44B KRW |
| Employees | 101 |
| Value | |
| P/B | 0.47x |
| P/S | 1.20x |
| FCF Yield | -15.67% |
| Profitability | |
| ROE | -2.06% |
| ROA | -1.60% |
| Op. Margin | -1.84% |
| Revenue Growth | -49.57% |
| Earnings Growth | -909.11% |
| Financial Health | |
| Debt Ratio | 128.28% |
| Total Debt | 10.00B KRW |
| FCF | -3.24B KRW |
| Cash | 5.48B KRW |
| Current Ratio | 2.88x |
| Performance | |
| 1Y Return | -24.02% |
| 1M Return | -8.33% |
| From 52W High | -42.37% |
| 1Y MDD | -48.90% |
| Trading | |
| Volume | 37,829 shares |
| Foreign Own. | 0.99% |
| Per Share | |
| EPS | -231 KRW |
| BPS | 5,432 KRW |
Company Info
Bifido, established in 1999 and listed on KOSDAQ in 2018, manufactures Bifidobacterium-based probiotics discovered in Korean infant intestines. It operates its own brand, Bifidolab, and provides domestic and international ODM services, possessing a proprietary patented strain, the sixth in the world to receive NDI and GRAS certifications from the US FDA. Through the development of MAP-based functional probiotics and eLBP microbiome therapeutics, Bifido is building a competitive pipeline targeting immune, cancer, and infectious diseases.